Story perspectives

AI in Drug Development: Rapid Growth Amid Challenges

4/1/2025

49 4

Summary

Story summary

Nearly half of organizations are now harnessing the power of AI and big data in drug development, a significant leap from 29% in 2019. While enthusiasm for digital tools is soaring—88% plan to boost their tech investments—only 13% have fully developed programs, highlighting ongoing hurdles like regulatory clarity and integration challenges.

History

Historical Context

The surge in AI and big data use in drug development mirrors past technological revolutions in healthcare, such as the Human Genome Project in the 1990s. This initiative transformed genetic research, much like today's digital tools are reshaping drug discovery. However, regulatory hurdles and integration challenges persist, echoing earlier struggles to adapt new technologies in medicine, highlighting the ongoing tension between innovation and regulation.

1 of 2

Story summary

Nearly half of organizations are now harnessing the power of AI and big data in drug development, a significant leap from 29% in 2019. While enthusiasm for digital tools is soaring—88% plan to boost their tech investments—only 13% have fully developed programs, highlighting ongoing hurdles like regulatory clarity and integration challenges.

1 / 2